Weight loss drugs outside stimulant ban 2027

The World Anti-Doping Agency (WADA) has announced that weight loss drugs such as "Ozempic" and "Mounjaro" will remain on the monitoring list in the 2027 list, despite not currently being classified as prohibited. This is due to ongoing scientific studies regarding their effects on athletic performance and the risk of misuse. The 2027 list will come into effect in January, with an annual review that could lead to their classification as prohibited if studies demonstrate that they provide an advantage or pose health risks, especially in sports that emphasize weight or physical appearance. According to the agency, the use of these drugs remains risky, with potential side effects such as nausea and muscle loss, which could harm athletic performance.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل